Trials / Terminated
TerminatedNCT05427396
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
A Phase I Clinical Study Evaluating the Safety, Tolerability,of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined Witht Oripalimab in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS004 | Usage and dosage: Inject 200mg once every 3 weeks |
| DRUG | Toripalimab Injection | Usage and dosage: Inject 240mg once every 3 weeks |
Timeline
- Start date
- 2022-07-28
- Primary completion
- 2024-01-15
- Completion
- 2024-01-15
- First posted
- 2022-06-22
- Last updated
- 2025-12-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05427396. Inclusion in this directory is not an endorsement.